Jaime Rodríguez-Vico

Jaime Rodríguez-Vico

Auto-generated profile, based on publicly available information

Jaime Rodríguez-Vico

Affiliation Headache Unit, Neurology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2025 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
MGMaría Clara García-Castillo
María Clara García-Castillo
AMAlvaro Sierra Mencia
Alvaro Sierra Mencia
ECEdoardo Caronna
Edoardo Caronna
DTDaniel Toledo-Alfocea
Daniel Toledo-Alfocea
AJAlex Jaimes
Alex Jaimes
AGAlicia Gonzalez-Martinez
Alicia Gonzalez-Martinez
Background: Preclinical evidence supports the immunoregulatory role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology. The increasing use of anti-CGRP therapies in patients with migraine and other comorbidities raises the question whether the potential use of anti-CGRP monoclonal antibodies (CGRP-mAbs) therapies in combination with other immunological therapies is effective and safe. Methods: This multicenter study included patients with migraine receiving CGRP-mAbs combined with immunosuppressive and immunomodulatory treatments. Clinical and demographic data, treatment history, laboratory markers and treatment-emergent adverse events (TEAEs) were analyzed. Effectiveness outcomes included the change in monthly migraine days (MMD) and monthly headache days (MHD) at 3, 6, 9 and 12 months, alongside the > 50% response rate. Moreover, autoimmune disease progression was also evaluated. We explored differences between patients with and without autoimmune disease activation. Results: Among 89 patients, there were 80 (90%) females with a mean age of 50 years (SD: 11), who had a high prevalence of psychiatric comorbidities (anxiety 44%, depression 49%) and medication overuse (68%). Patients receiving immunological treatments experienced significant reductions in MMD and MHD, with MMD decreasing from 16 (SD: 7) at baseline to 9 (SD: 8) at 6 months, and MHD dropping from 23 (SD: 8) to 17 (SD: 11). A 50% response in MMD was achieved by 46% at 6 months. TEAEs were reported in 28%, most commonly constipation (16%) and dizziness (9%). Conclusions: CGRP-mAbs therapies combined with immunological treatments appear effective and safe in patients with autoimmune diseases. Larger prospective studies are necessary to confirm these findings and optimize management strategies.

1 April 2026 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Open access
MGMaría Clara García‐Castillo
María Clara García‐Castillo
AMAlvaro Sierra Mencia
Alvaro Sierra Mencia
ECEdoardo Caronna
Edoardo Caronna
DTDaniel Toledo‐Alfocea
Daniel Toledo‐Alfocea
AJAlex Jaimes
Alex Jaimes
AGAlicia Gonzalez-Martinez
Alicia Gonzalez-Martinez
Objective: This study aimed to evaluate demographic characteristics, treatment effectiveness, and safety outcomes in patients with migraine undergoing anti‐calcitonin gene‐related peptide (CGRP) treatments regarding the presence of autoimmune diseases. Background: CGRP has an important role in migraine pathophysiology through neuronal modulation in the trigeminovascular nociceptive system and activation of neuro‐inflammatory cascades. We hypothesized that autoimmune diseases may influence treatment response and safety profiles in patients with migraine treated with anti‐CGRP treatments. Methods: This was a retrospective multicenter, age‐ and sex‐matched cohort study in headache units/headache clinics in Spain and United Kingdom between May 2024 and May 2025 including patients treated with CGRP monoclonal antibodies from prospectively collected cohorts. Patients were assessed for demographics, migraine‐related characteristics, treatment effectiveness (monthly migraine days [MMD] and/or monthly headache days [MHD]), and safety outcomes. The main outcome was the effectiveness measured by ≥50% response rate in MMD between the two groups. Secondary outcomes included other effectiveness measurements regarding the number of MMD and MHD and treatment emerging adverse events. Results: A total of 388 patients with migraine under anti‐CGRP treatments (194 with autoimmune diseases and 194 age‐ and sex‐matched controls without autoimmune diseases) were included. The proportion of patients achieving a ≥50% response rate in MMD was higher in patients without autoimmune diseases at 6 (69% vs. 53%; p = 0.006) and 9 months (74% vs. 52%; p = 0.006). Treatment emerging adverse events were comparable between the two groups (35% vs. 38%; p = 0.575). Patients with autoimmune disease had a significantly lower likelihood of achieving a ≥50% response in MMD compared with those without autoimmune disease (adjusted odds ratio, 0.61; 95% confidence interval, 0.44–0.85; p = 0.006), independent of comorbid depression and medication overuse. Conclusions: Our study shows that anti‐CGRP treatments are effective and safe for patients with migraine regardless the presence of autoimmune diseases, although an increased treatment response in patient without autoimmune disorders compared to patients with autoimmune disorders was observed. These findings highlight the need for early intervention, tailored strategies, and vigilant monitoring in patients with migraine and autoimmune disorders. Further research should explore immunomodulatory approaches to enhance outcomes. image

8 June 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Gabriele BertottiGabriele Bertotti
Gabriele Bertotti
ARAlberto Roldán Ruiz
Alberto Roldán Ruiz
JRJaime Rodríguez-Vico
Jaime Rodríguez-Vico
AGAndrea Gómez-García
Andrea Gómez-García
PMPaula Marrero-Fernández
Paula Marrero-Fernández
MLMiguel López-Moreno
Miguel López-Moreno
Introduction: Migraine is a highly disabling neurological disorder characterized by recurrent headache attacks and altered pain processing. Emerging evidence suggests that dietary patterns rich in antioxidant compounds may modulate migraine-related pathophysiology, yet the specific association between polyphenol intake and objective pain sensitivity measures remains unclear. This study aimed to examine the association of dietary polyphenol with pain sensitivity and migraine-related disability in individuals with migraine. Materials and methods: This cross-sectional study including 72 adults (65 women) with a confirmed migraine diagnosis according to ICHD-III criteria. Participants completed a 3-day dietary record, and polyphenol intake was estimated using the Phenol-Explorer database. Clinical outcomes included pressure pain thresholds (PPTs) at trigeminal and extratrigeminal sites, migraine-related disability (MIDAS), perceived stress (PSS), and handgrip strength. Associations were analyzed using Pearson correlations and multiple linear regression models adjusted for age, sex, BMI, energy intake, and comorbidities. Results: Participants with longer disease duration reported higher polyphenol intake (p < 0.05). Total polyphenol intake was positively correlated with PPTs at the masseter (r = 0.27) and middle temporalis (r = 0.31), and inversely correlated with MIDAS scores (r = −0.25, all p < 0.05). In adjusted regression analyses, higher polyphenol intake predicted increased PPTs (masseter: β = 0.33; middle temporalis: β = 0.38) and lower MIDAS scores (β = −0.25, all p < 0.01). No associations were observed with handgrip strength or perceived stress. Conclusions: Higher dietary polyphenol intake was associated with reduced pain sensitivity and lower migraine-related disability, suggesting a potential role for polyphenol-rich diets in migraine management. Further randomized controlled trials are needed to confirm these associations and explore the mechanisms through which polyphenol-rich diets may influence migraine-related outcomes.

20 November 2025 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
AJAlex Jaimes
Alex Jaimes
JRJaime Rodríguez-Vico
Jaime Rodríguez-Vico
OPOlga Pajares
Olga Pajares
PVPaloma Valín-Villanueva
Paloma Valín-Villanueva
AHAnna Lena Nystrom Hernández
Anna Lena Nystrom Hernández
Jesus Porta EtessamJesus Porta Etessam
Jesus Porta Etessam

15 September 2026 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
AGAna Beatriz Gago-Veiga
Ana Beatriz Gago-Veiga
ARAna Belen Lopez Rodriguez
Ana Belen Lopez Rodriguez
BCBlanca Hoyas Cruz
Blanca Hoyas Cruz
AJAfrica Garrido Jimena
Africa Garrido Jimena
Nuria MontesNuria Montes
Nuria Montes
IFIris Fernández-Lázaro
Iris Fernández-Lázaro
Background: Short- and mid-term real-world data support the effectiveness of atogepant for migraine prevention, but evidence beyond 6 months remains scarce. This study evaluated the 12-month effectiveness, safety, persistence, and predictors of response in a large treatment-resistant migraine cohort. Methods: This prospective multicentre study enrolled patients from 15 tertiary Headache Units in Spain within the GEMA Project. Clinical and demographic characteristics, previous and concomitant preventive treatments, monthly headache days (MHD), monthly migraine days (MMD), and adverse events were systematically collected at baseline and after 3, 6, and 12 months. In a subset of patients, Headache Impact Test (HIT-6), Hospital Anxiety and Depression Scale (HADS), and Insomnia Severity Index (ISI) were also assessed. Results: A total of 513 patients were included. The cohort showed marked treatment resistance, with a median of 6 previous preventive failures; 74% ( n = 380) had chronic migraine, 84% ( n = 423) had previously failed onabotulinumtoxinA, and more than half had prior exposure to anti-CGRP monoclonal antibodies ( n = 270). Treatment persistence was approximately 80% at 6 months ( n = 409) and 60% at 12 months ( n = 304), with lack of effectiveness as the main reason for discontinuation. Among patients remaining on treatment with complete data at all follow-up visits, median MHD decreased from 20 days at baseline to 10 days at 3 months and 9 days at 6 months, remaining stable at 9 days at 12 months. Median MMD decreased from 13 days to 6 days at 3 months, 5 days at 6 months, and remained at 5 days at 12 months ( p < 0.0001 versus baseline for all time points). At 12 months, ≥ 50% response rates were 52.3% for MHD and 57.8% for MMD in the observed-case analysis, and approximately 31% and 33%, respectively, using non-responder imputation in the full baseline cohort. Improvements in disability and medication overuse were observed, while exploratory analyses in smaller subsets suggested improvements in anxiety, depression, and insomnia. A greater burden of previous preventive treatment failures independently predicted lower odds of achieving a ≥ 50% response at 12 months. The frequency of most reported adverse events was lower at later follow-up visits, and no new safety signals emerged. Conclusions: Atogepant was associated with maintained clinical benefit over 12 months among patients who remained on treatment, with a favourable long-term safety profile in a highly treatment-resistant migraine population. Greater previous preventive failure burden predicted lower response rates, reinforcing the importance of earlier preventive optimisation. Trial registration: ClinicalTrials.gov, NCT07699549, retrospectively registered on 8th of July 2026.

29 August 2026 in Nutrition Research
Verified
Journal Article
Open access
ARAlberto Roldán Ruiz
Alberto Roldán Ruiz
Gabriele BertottiGabriele Bertotti
Gabriele Bertotti
JRJaime Rodríguez-Vico
Jaime Rodríguez-Vico
AGAndrea Gómez-García
Andrea Gómez-García
PMPaula Marrero-Fernández
Paula Marrero-Fernández
MLMiguel López-Moreno
Miguel López-Moreno